Models of prion disease

   
   

The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrP.sup.C and 2) proper cellular localization, i.e. an ability to be transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious prions. The invention further provides systems for the study of prion disorders and methods of using these systems, e.g. the study of the mechanical processes in progression of prion-mediated disease or the identification of new therapeutic agents for treatment of prion-mediated disorders. In such systems, protease-resistant under-glycosylated PrP is generated de novo and can be detected by standard immunoblot techniques.

A invenção atual fornece uma proteína de PrP da novela, e os ácidos nucleic que codificam esta proteína, onde a proteína de PrP é caracterizada em vivo 1) pelo glycosylation relative.to do glycosylation incompleto do selvagem-tipo PrP.sup.C e 2) pelo localization celular apropriado, isto é uma abilidade de ser transportado à superfície da pilha. Esta novela, PrP sob-under-glycosylated, ao contrário de suas contrapartes celulares normais, pode fàcilmente ser convertida em um isoform protease-resistente pelo incubation com prions infectious. A invenção mais adicional fornece sistemas para o estudo de disorders do prion e de métodos de usar estes sistemas, por exemplo o estudo dos processos mecânicos na progressão da doença prion-mediada ou na identificação de agentes therapeutic novos para o tratamento de disorders prion-mediados. Em tais sistemas, PrP sob-under-glycosylated protease-resistente é de gerado novo e pode ser detectado por técnicas padrão do immunoblot.

 
Web www.patentalert.com

< Purified and isolated serine-threonine kinase receptors associated protein and use of same in the modulation of the biological activity of TGF-.beta.

< Recombinant antibacterial group IIA phospholipase A2 and methods of use thereof

> Vaccine based on attenuated Haemophilus somnus

> Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis

~ 00123